![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=737172488413601)
basal insulin and glp-1
Shipping Estimate
basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]
USD29.64
USD53.64
Pay in 4 interest-free payments of $7.41 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 14 - Nov 19
![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://s3.amazonaws.com/production.scholastica/public/attachments/9c499677-aa6b-4e1e-9360-4d7e41721fd8/large/figure_1._mechanism_of_synthesis_of_glp-1.png)
![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13098-025-01623-w/MediaObjects/13098_2025_1623_Figa_HTML.png)
![basal insulin and glp-1 Adding a receptor agonist was not associated with a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation glp-1_analogs [TUSOM | Pharmwiki]](https://diatribe.org/cdn-cgi/image/width=3840,format=auto,dpr=1,fit=cover,height=1524/https://api.diatribe.org/sites/default/files/inline-images/screen-shot-2024-09-16-at-4.59.40-pm.png)
